Certified by Founder
Lodge
DISCO Pharmaceuticals GmbH
start up
Germany
- Cologne, North Rhine-Westphalia
- 17/01/2024
- Seed
- $21,727,000
DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.
- Industry Pharmaceutical Manufacturing
- Website https://discopharma.de/
- LinkedIn https://www.linkedin.com/company/disco-pharmaceuticals-gmbh/about/